Cytiva introduces next-generation Biacore 8 series SPR systems for faster, more confident drug discovery

May 20, 2026

• New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system
• Biacore Insight Software v7.0 adds Sensorgram comparison for objective similarity scoring

Cytiva, a Danaher company and a leader in the life sciences industry, is introducing the next generation of its Biacore 8 series SPR systems, enabling scientists to generate reliable interaction data faster, as drug discovery grows more complex. The new Biacore 8S and Biacore 8S+ systems bring together rapid screening and high-quality molecular characterization in a single system, reducing hands-on time through integrated plate handling, automated workflows, and extended unattended operation, without compromising data quality.

Tim Bervoets, President, Discovery & Medical, Cytiva, says: “Scientists are being asked to move faster while working with increasingly complex molecules and tighter resources. The next generation of Biacore 8 series systems is designed to help teams focus their time and investment on the most promising candidates by delivering confident interaction data earlier in the discovery process.”

The systems can screen 384 proteins in approximately 15 minutes, 16 times faster than the previous generation. This allows scientists to scale screening activities, while further improving the ability to resolve the most challenging interactions in late-stage characterization.

As part of this update, Cytiva is also advancing its Biacore Insight Software v7.0 with Sensorgram comparison, a feature that converts full interaction profiles into an objective similarity score. This gives scientists a clearer way to assess comparability against a reference sample and supports applications such as biosimilar comparability, batch-to-batch monitoring, and assessing the impact of process and formulation changes. It also supports outputs aligned with comparative analytical assessment and 21 CFR Part 11 compliance.

The Biacore 8S and Biacore 8S+ systems and the Biacore Insight Software v7.0 will be available to order in the summer of 2026.

Cytiva, the drop logo,Biacore 8S system, Biacore 8S+ system, Biacore 8 series SPR system, and Biacore Insight Software with Senorgam comparison are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

---

Media contact:

Colleen Connolly
Colleen.Connolly@cytiva.com

About Cytiva

At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.